California Department of Public Health

### **Antimicrobial Resistance (AR)**





# Agenda

- Introduction
- Overview of the Antimicrobial Resistance Module
- AR Data Requirements
- NHSN Metrics and Benchmarks
- CDA and the NHSN HAI IG
- Our Support
- Resources



### Speaker

#### **KP** Sethi

- Director of Information Analysis and Technology
- Lead Analyst
- Quality and public health reporting expert



# **Project Background**

### • Project Goal


Provide technical assistance to the CDPH HAI Program and California hospitals implementing National Healthcare Safety Network (NHSN) Antimicrobial Use and Resistance Reporting

### Background

- CDPH distributed two surveys in 2015 to identify California hospitals with sufficient informatics capabilities to monitor AU and AR data with NHSN
- Progress requires assistance in implementing AUR reporting



### **Organizations Involved**






# Agenda

- Introduction
- Overview of the Antimicrobial Resistance Module
- AR Data Requirements NHSN Metrics and Benchmarks
- CDA and the NHSN HAI IG
- Our Support
- Resources




### **NHSN Goals**





### **CDC NHSN Structure**





Antimicrobial Use and Resistance Reporting


Antimicrobial Use Option

Tracks usage of antimicrobials across inpatient locations Antimicrobial Resistance Option

Tracks the resistance of antimicrobials across inpatient locations

AUR Module allows choice of AU, AR, or both





AUR allow manual data entry.

#### **Electronic Data Submission**

All modules can submit electronic data, which is a requirement for the AUR module.



## **Electronic Data Submission**



Electronic Submission requires the HL7 Clinical Document Architecture (CDA) format.



Hospitals submit data via the NHSN Portal.

Submitted data are analyzed and benchmarked.



# **NHSN CDA Submission Format**

- HL7 Clinical Document Architecture (CDA)
  - Standard for electronic clinical documents
  - -Used in Meaningful Use
  - -Generic format for all NHSN HAI Modules
  - Specific document types per reporting option



# **AR Option**

#### **Objectives**

- Evaluate AR data with a standardized approach
- Facilitate regional and national AR assessment

#### Benefits

- Improve awareness of AR problems
- Aid decision making and prioritize transmission prevention efforts
- Provide benchmarking to aid regional and national tracking



# **Meaningful Use and AUR Reporting**

- (f)(6) Transmission to Public Health Agencies Antimicrobial Use and Resistance Reporting
- Create antimicrobial use and resistance reporting information for electronic transmission in accordance with the standard in § 170.205(r)(1).

§170.315(f)(7)	Transmission to public health agencies — health care surveys	Guide	06-04-2018	Test Procedure	10-06-2016	Testing
----------------	--	-------	------------	-------------------	------------	---------



# Agenda

- Introduction
- Overview of the Antimicrobial Resistance Module
- AR Data Requirements
- NHSN Metrics and Benchmarks
- CDA and the NHSN HAI IG
- Our Support
- Resources



# **Minimum Requirements to Report AR**

- Facilities enrolled in NHSN are:
  - General acute care hospitals
  - Critical access hospitals
  - Oncology hospitals
  - Long term acute care hospitals
  - Inpatient rehabilitation facilities
- NHSN does not support data submission for the AR Option from long term care facilities (i.e., skilled nursing facilities, nursing homes) or outpatient dialysis facilities.
- Collect the numerator and denominator data electronically.
- Upload data into NHSN with CDA specifications.



### **AR Data Elements**

- Facilities report 2 types of data each month:
  - Numerator (Multiple files)
  - Denominator (Single file)
- Numerator: Patient-level susceptibility results for specific organisms
- Denominator: Patient days and admissions (facility-wide only)



## **System Requirements**

- Denominator: Patient Days and Admissions
  - Admission Discharge Transfer System
  - Tracking patient flow by location, and time
- Numerator: Patient-level Isolate Report
  - Lab Information System
  - Isolate Susceptibility report including organism, source, time and location where collected, and antimicrobial susceptibility test results.



## **NHSN AR Denominator**

- Typically calculated using ADT data
- Counts are collected at the Facility Level
- NHSN AUR Module guide suggests reporting from all patient care locations is technically easier than from selected locations.



### **Denominator Data Elements**

### Facility-Level Data

- Unique NHSN Facility ID
- Location
- Month
- Year

### **Patient Days**

**Admission Count** 



### **Denominator Data**

- Each month, across all inpatient units:
  - Patient Days:
    - Number of patients present in the facility at a specific time on each day
    - Usually, midnight census (AKA butts in bed)
  - Admissions:

Number of patients admitted to an inpatient location in the facility

- Calculated from A/D/T Data
- No denominator data for outpatient locations



# **Calculating Patient Days**

	Patient Movement	Patient Days (Census Count)
Patient A	Medical Ward: 00:01-24:00	Medical Ward = 1
Patient B	Medical ICU: 00:01-24:00	Medical ICU = 1
Patient C	Medical ICU: 00:01-08:30 Medical Ward: 08:31-24:00	Medical ICU = 0 Medical Ward = 1
Patient D	Medical ICU: 00:01-10:00 Step Down: 10:01-15:00 Medical Ward: 15:01-24:00	Medical ICU = 0 Step Down = 0 Medical Ward = 1
Totals:		Medical Ward = 3 Medical ICU = 1 Step Down = 0



# **NHSN AR Numerator**

- Patient-level susceptibility results for specific organisms
  - Patient data:
    - DOB, gender, date admitted to facility, location
  - Specimen data:
    - Collection date, Source
  - Susceptibility data:
    - Organism
    - Antimicrobial susceptibility data
      - For each antimicrobial required for the isolate organism/specimen type
    - Final lab interpretation
- Hospitals use LIS to gather this data.



### **Numerator Data Elements**

#### **Facility Identifier**

Unique NHSN Facility ID (i.e., Object Identifier [OID] in the CDA)

#### Patient Data

- Patient identifier
- Date of birth
- Gender
- Date admitted to facility (use the encounter date if the event occurred in outpatient location)

#### Specimen Data

- Specimen collection date
- Specimen source
- Location code (mapped to CDC location codes)
- Isolate identifier (unique isolate ID in the electronic laboratory report)
- Organism



### **Numerator Data Elements**

#### Antimicrobial Susceptibility Data

- Antimicrobial
- PBP2a-agglutination (only if Staphylococcus aureus)
- PCR mec-gene (only if Staphylococcus aureus)
- E-test sign
- E-test value and unit of measure
- Interpretation of E-test
- MIC sign
- MIC value and unit of measure
- Interpretation of MIC test
- Disk diffusion (KB) test sign
- Disk diffusion (KB) test value and unit of measure
- Interpretation of disk diffusion (KB) test
- Final interpretation result



# **AR vs AU Reporting**

### – Denominator:

- AU: Days Present count
- AR: Patient Days count

– Numerator:

- AU: Days of Therapy for 90 antimicrobials, for each location
- AR: Isolate Reports for Organisms in any inpatient location

- Location Data:

- AU: All collected, and reported by location
- AR: Facility-wide for inpatient locations



# **AR vs AU Reporting**


- Different Source Systems:
  - AU requires data from ADT and eMAR systems
  - AR requires data from LIS and ADT systems
- Data Sensitivity:
  - AU is summary data, with no PHI
  - AR reports contain patient level data
- CDA Reports:
  - AU reporting requires 1 file per location
  - Each files contain numerator and denominator
  - AR reporting requires 1 file per isolate
  - Denominator is a separate file, for entire facility



# **Location Mapping in AR**

- Hospitals reporting HAI have Inpatient Locations mapped in NHSN.
- AUR uses same location mapping to identify locations.
- Hospitals do not report Antimicrobial Resistance by location.
- Isolate reports derive from all inpatient locations or select outpatient locations.





# **Eligible Organisms**

- Full List: Appendix A, NHSN AUR Guide
- Antimicrobials required for resistance testing

Organism	Specimen Type	Antimicrobial Agents
Acinetobacter	Blood, Urine, Lower	Amikacin
(All Acinetobacter species	Respiratory, CSF	Ampicillin-sulbactam
noted in the IDM/Pathogen		Cefepime
Codes tab listed in the		Cefotaxime
ARO Pathogen column)		Ceftazidime
		Ceftriaxone
		Ciprofloxacin
		Doxcycline
		Gentamicin
		Imipenem with Cilastatin
		Levofloxacin
		Meropenem
		Minocycline
		Piperacillin
		Piperacillin-tazobactam
		Tetracycline
		Ticarcillin-clavulanate
		Tobramycin
		Trimethoprim-sulfamethoxazole
	Additional Agents for Urine	None



# **Eligible Isolates**

- Report all required data each month for each eligible isolate-based report
- Inpatient or specific outpatient locations (i.e., ED, pediatric ED, and 24-hour observation)
- Regardless of antimicrobial resistance

- Even if susceptible to all required antimicrobials



# Lab Reporting Guidelines

- Interpretation of test results (i.e., E-test, MIC test, Disk diffusion [KB] test):
  - S = Susceptible
  - S-DD = Susceptible-Dose Dependent
  - I = Intermediate
  - R = Resistant
  - NS = Non-Susceptible
  - N = Not Tested
- Specific to Gentamicin and Streptomycin results for Enterococcus testing:
  - S = Susceptible/Synergistic
  - R = Resistant/Not Synergistic
- Facilities should only report final or corrected susceptibility testing.



### **Electronic Calculation Requirement**

- Facilities should not employ manual data collection to report AR.
- Facilities that cannot electronically obtain the results of the individual laboratory tests should:
  - Use 'Unknown' or 'Not Tested'
  - Provide the final interpretation result



# **Specimen Types**

- Two distinct sources are reported:
  - Invasive Specimen: Blood or cerebrospinal fluid
  - Non-Invasive Specimen: Lower respiratory or urine
- Different sources, different "AR Events"



# **Reporting Rules for Specimen Sources**

Invasive Sources

Each eligible organism isolated from an invasive source (i.e., blood or CSF) per patient, per 14-day period, across calendar months

Non-Invasive Sources

First eligible organism isolated from an eligible noninvasive culture source (i.e., lower respiratory or urine), per patient, per month



# **Edge Case: Report Non-Required Drugs**


- Isolate is eligible for reporting even if:
  - All of the NHSN required antimicrobials were not tested
  - At least one non-required drug is eligible
- Example:
  - Oritavancin is not a required antimicrobial for the Staphlococcus aureus isolate
  - None of the 23 required antimicrobials were tested
  - Isolate is still considered eligible for reporting



# **Reporting for Non-Required Drugs**

- For such an isolate, the facility will:
  - Report the specimen.
  - Report "Not Tested" for all required drugs.
  - Exclude the susceptibility information for
     Oritavancin because it not in the drug panel for that organism.





#### 

# **Invasive Specimen Reporting**

- The 14-day Rule for Invasive Specimens:
  - Record an AR Event after 14 days with no positive culture result from the laboratory if the patient and specific organism pass.
- Record an AR Event for:
  - Each eligible organism isolated from an invasive source (i.e., blood or CSF)
  - Per patient
  - Per 14-day period
  - Across Calendar Months



# 14 Day Rule


- Additional Guidance for the 14 day Rule:
  - Count starts on the day of specimen collection
  - Only applies to those specimens from an inpatient location or select outpatient location (i.e., ED, pediatric ED, or 24-hour observation area)

Exclude cultures from other healthcare facilities

• At a maximum, there will be no more than three invasive isolates per specific organism per patient per month.



#### **Algorithm for Invasive Specimen**



Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	ood Sulfamethoxazole E-test with	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Eviffu			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
				14 day rule when ces are invasive	n	Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final nte			Final Interpretation	Susceptible
2018- 02-24		Chloramphenicol	E-test	Susceptible	vofloxacin	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml Resistant
			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible		Minimum inhibitory concentration (MIC)	N/A
42			Final Interpretation	Susceptible		Final Interpretation	Resistant


Date	Source	Antimicrobial	Test	Results	Antimicrobi	Test	Results
		Agent		eport to NHSN	lagent		
2018- 02-20	Blood	Sulfamethoxazole c-test with		is the first blood	eftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethopum	Disk Diff	ure collected for		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Mini nur this patient			Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final Interpretation	n Resistant		Final Interpretation	Susceptible
2018- 02-24	CSF	Chloramphenicol	E-test	Less than 0.1 ug/ml Susceptible	Levofloxacin	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitor concentration (MIC			Minimum inhibitory concentration (MIC)	N/A
			Final Interpretatio	n Susceptible		Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml Resistant
			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate		Disk Diffusion (KB)	N/A
			Minimum inhibitor concentration (MIC			Minimum inhibitory concentration (MIC)	N/A
43			Final Interpretatio	n Susceptible		Final Interpretation	Resistant

Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with	E-test Greater than 5.0 ug/ml C Resistant		Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Diffusion (KB) N/A	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhibitory	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final Int DO NO	t report to NHSN		Final Interpretation	Susceptible
2018- 02-24	CSF	Chloramphenice	E-test It has	been less than 14	evofloxacin	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diff day	s since the last		Disk Diffusion (KB)	N/A
			Mini nur positiv			Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml Resistant
			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible		Minimum inhibitory concentration (MIC)	N/A
44			Final Interpretation	Susceptible		Final Interpretation	Resistant

Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			<b>Final Interpretation</b>	Resistant		<b>Final Interpretation</b>	Susceptible
2018- 02-24			E-test	Less than 0.1 ug/ml Susceptible	Levofloxacin	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory N/A concentration (MIC)		Minimum inhibitory concentration (MIC)	N/A	
			Final Int Report to NHSN			Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test It has b	een more than 14	eftazidime	E-test	Greater than 5.0 ug/ml Resistant
	Mini mu		s since the last		Disk Diffusion (KB)	N/A	
			Mini nui	0.1 ug/ml Susceptible		Minimum inhibitory concentration (MIC)	N/A
45			Final Interpretation	Susceptible		Final Interpretation	Resistant

#### Walkthrough: 14 Day Rule Data Reported

Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			<b>Final Interpretation</b>	Resistant		<b>Final Interpretation</b>	Susceptible
<del>2018-</del> <del>02-24</del>		Chloramphenicol	<del>E-test</del>	Less than 0.1 ug/ml Susceptible	<del>Levofloxacin</del>	<del>E-test</del>	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (KB)	<del>N/A</del>		Disk Diffusion (KB)	<del>N/A</del>
			Minimum inhibitory concentration (MIC)	<del>N/A</del>		Minimum inhibitory concentration (MIC)	<del>N/A</del>
			Final Interpretation	Susceptible		Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml Resistant
			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible		Minimum inhibitory concentration (MIC)	N/A
46			Final Interpretation	Susceptible		Final Interpretation	Resistant




#### **Non-Invasive Specimen Reporting**


- Record an AR Event for:
  - First eligible organism isolated from an eligible non-invasive culture
  - Each patient
  - Each month
- NHSN only allows one AR event for lower respiratory or urine specimens per month per patient, per organism.



#### Non Invasive Specimen Algorithm



**PublicHealth** 



#### **Duplicate Isolates**

- Duplicate Isolates
  - Defined as same species or same genus from same patient on same day
  - Isolates must have the same source type (i.e., invasive or non-invasive)
- Handling multiple isolates of the same organism
  - Isolates may produce conflicting results
  - Facilities should only report one isolate to NHSN
  - NHSN has rules for removing duplicates



- General rules:
  - Do not merge test results across multiple isolates
  - Don't summarize results across different isolates tested on same day
  - Eliminate isolates on same day without susceptibility test results
  - For Invasive Specimens:
    - CSF isolates > blood isolates
  - For Non-Invasive Specimens:
    - lower respiratory isolates > urine isolates



#### **Duplicate Isolate Scenarios: Conflicting Results**

- 1. Same isolate tested using the same test, with conflicting results
- 2. Same isolate tested using different tests, with conflicting results
- Two isolates collected on the same day return conflicting results from a panel of antimicrobial tests



- Same isolate, same specific test, conflicting results:
  - If available, report the final interpretation
  - Without a final interpretation, report the most resistant interpretation (i.e., NS > R > I > S-DD > S > NT)
- Example:
  - Interpretation of E-test 1 = Intermediate
  - Interpretation of E-test 2 = Susceptible
  - Report E-test 1/ Intermediate as final interpretation



- Same isolate, different specific tests, conflicting results:
  - If available, report the final interpretation
  - If no final interpretation is provided, report the most resistant interpretation (i.e., NS > R > I > S-DD > S > NT).
- Example:
  - Interpretation of MIC test = Resistant
  - Interpretation of E-Test = Intermediate
  - No final interpretation was provided
  - Report "Resistant" as the final interpretation



- Different isolates, specific tests, conflicting results:
  - If available, report isolate with the most resistant final interpretation.
  - If no final interpretation, report the isolate with the higher amount of drug resistance based on the number antimicrobials testing "NS" or "R".
  - If all else fails, report first isolate entered into LIS
- Example: *Candida albicans,* isolated from two blood specimens, same patient, same calendar day, no final interpretation
  - First isolate tested "R" to 3 of 8 antimicrobials
  - Second isolate tested "R" to 4 of 8 antimicrobials
  - The facility reports the second isolate to NHSN because it showed greater resistance



# Walkthrough: Deduplication

Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			<b>Final Interpretation</b>	Resistant		Final Interpretation	Susceptible
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Non-Susceptible

Scenario:

Two isolates from same day, conflicting results to

panel of antimicrobials



# Walkthrough: Deduplication

Date	Source	Antimicrobial Agent	Test	Results		Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxa: ole with			) ug/ml	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimetnoprim	Collected on the sam day	he same			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			,				Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final interpretation	Resistant			Final Interpretation	Susceptible
2018- 02-20		Sulfamethoxazole with Trimethoprim	E-test	Less than 0.1 u Susceptible	g/ml	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk Diffusion (KB)	N/A			Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A			Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible			Final Interpretation	Non-Susceptible



#### **Verification Walkthrough: Deduplication**

			Test	Results	Antimicrobi al agent	Test	Results
Conflicting Results		E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible	
		Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate	
			Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
		<	<b>Final Interpretation</b>	Resistant	<	<b>Final Interpretation</b>	Susceptible
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Non-Susceptible



#### **Verification Walkthrough: Deduplication**


Date	Source	Antimicrobial Agent	Test		Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with	E-test		Greater than 5.0 ug/ml Resistant		E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Di	Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minir conce				Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final				Final Interpretation	Susceptible
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-tesi		most resistant result	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk [				Disk Diffusion (KB)	N/A
				1inimum inhibitory N/A oncentration (MIC)			Minimum inhibitory concentration (MIC)	N/A
			Final I	Interpretation	Susceptible	<	Final Interpretation	Non-Susceptible



#### Verification Walkthrough: Deduplication Data Reported

Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
<del>2018-</del> <del>02-20</del>	Blood	Sulfamethoxazole with	<del>E-test</del>	Greater than 5.0 ug/ml Resistant	<del>Ceftazidime</del>	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	<del>Disk Diffusion (KB)</del>	<del>N/A</del>		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final Interpretation	Resistant		Final Interpretation	<b>Susceptible</b>
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Non-Susceptible





# **AR Monthly Data Submission**

- Locations and Timeline:
  - Submit data from all NHSN-defined inpatient locations
     Beginning January 1, 2017, facilities can submit AR specimens from three
    - outpatient locations: ED, pediatric ED, and 24-hour observation area
  - Upload within 30 days of completion
- Submit:
  - One CDA file per organism (AR Event)
  - One CDA file for denominator
  - Example:
    - 50 separate CDA files for 50 separate AR Events
    - One CDA for facility-wide denominators
    - All CDA files are uploaded in one Zip file
    - Max: 1000 CDAs or file size of 2 MB per zip file



# Agenda

- Introduction
- Overview of the Antimicrobial Resistance Module
- AR Data Requirements
- NHSN Metrics and Benchmarks
- CDA and the NHSN HAI IG
- Our Support
- Resources



# **Benchmarks for AR Reporting**

- AR Option Metrics:
  - Metrics at the monthly, quarterly, semi-annual, or annual period depend on the frequency the isolates occur.
  - Facility-wide antibiogram
  - Stratified by specimen source, time period, specific antimicrobial, and organism



# **Facility Wide Antibiogram**

For each organism-antimicrobial pairing\*

Percentage of Non-susceptible =

Total # of organisms resistant or intermediate for a pathogen **Divided By** 

Total # of organisms tested for that pathogen

\*exceptions based on organism species



# **Benchmarks for AR Reporting**

- AR Option Line List:
  - Show all AR Events for a given time period
  - Most customizable report
  - Displays:
    - AR Event
    - Patient ID
    - Date of birth
    - Gender
    - NHSN assigned Event ID
    - Specimen type
    - Organism identified.
  - Customizations show specific months, locations, organisms, and test results.
  - Helpful when validating the data after upload.
- NHSN can export all AR Option data in various formats (CSV etc...)



# Agenda

- Introduction
- Overview of the Antimicrobial Resistance Module
- AR Data Requirements
- NHSN Metrics and Benchmarks
- CDA and the NHSN HAI IG
- Our Support
- Resources




# CDA R2

- Clinical Document Architecture (CDA)
- Common model defining the structure and semantics of clinical documents
- Developed by Health Level Seven
- XML syntax
- First released in 2005



#### **CDA Body and Header**



- Specific Tests
- Results



# **Object Identifier (OID)**

- A unique identifier that represents an object:
  - A tree of nodes and edges (i.e., branches and leaves, sometimes called OID arcs)
  - A positive integer is assigned to each edge in the tree.
- OIDs in CDA:
  - Add global uniqueness to identifiers in clinical documents.
  - Identify the Facility submitting data to NHSN
  - Identify the vocabulary terminology systems in a document.



# HL7 V3 Data Types: R1 in CDA

	Organism Codes				
BASIC D	Antimicrobial Agents	CODED	VALUES		
ANY	Drug Susceptibility	CS	Coded Simple		
BL	Tests	CE	Code Value		
ED	Encapsulated data	CD	Coded with Equivalence		
ST	Character String				
NAMES		ADDRESSES			
PN	OIDs	ADXP	Address Part		
ON		AD	Postal Address		
COLLECT		IDENTIFIERS			
SET	Set	Ш	Instance Identifier		
LIST	List	<b>COMM</b> Ι	JNICATIONS		
IVL	Interval	TEL	Telecommunication Address		
QUANTI	TIES	TIME			
INT	Integer	TS	P		
PQ	Physical Quantity	PIVL Patient Days			
REAL	Real	IVL	Ir		
RTO	Ratio	GTS	General mining speemeation		



## Value Sets and Code Systems

- Code a sequence of characters assigned meaning by some formal system
   Expression, Symbol
- Code System formal definitions that define the meaning of a set of concepts, with codes
  - Terminology, Ontology, Enumeration, Classification...
  - SNOMED, LOINC, RxNorm
  - Drive meaning/analysis off code systems
- Value Set a group of code/codeSystem pairs
  - Doesn't define it's own codes
  - Picks codes from multiple code systems
  - AR examples:
    - Isolate Codes
    - Specific Tests performed



#### Example of Code System Vs. Value Sets

- Ice Cream flavors code system
  - Chocolate
  - Vanilla
  - Strawberry
  - Mango
  - Pear
  - Rocky Road
  - Cookie Dough
  - Cake
  - Caramel
  - Coffee
  - Blueberry
  - Raspberry

- "Berry Flavors" Value Set
  - Strawberry
  - Blueberry
  - Raspberry



#### **Code Systems**

- **SNOMED-CT:** Systematized Nomenclature Of Medicine Clinical Terms
  - Specimen Type (codes for invasive/non-invasive)
  - Pathogen Identified
- LOINC: Logical Observation Identifiers Names and Codes
  - Document and section codes
  - Antibiotic susceptibility tests
- RxNorm: RxNorm provides normalized names for clinical drugs
  - Antimicrobial ingredients



## Tools

- Tools find codes from the three hierarchies:
  - SNOMED Browser
  - LOINC on-line (<u>LOINC.org</u>)
  - RxNorm's <u>RxNav</u>
- Finding value sets:
  - <u>Value Set Authority Center (VSAC)</u>: https://vsac.nlm.nih.gov
    - General Source of truth for most (all) Value Sets
  - <u>HAI Specific Values Sets Excel Spreadsheet</u> https://gforge.hl7.org/gf/project/strucdoc/scmsvn/?action =browse&path=/\*checkout\*/trunk/HAI/HAI-R1-Normative\_XML\_Support\_Files/hai\_voc.xls&revision=182



#### **SNOMED Browser**

SNOMED Internat	onal S	NOMED CT Browser		ase: United States Edition 20170901   Perspective: Full	Feedback	About 👻 🔤	- SNOMED	Leading healthcare terminology, worldwide
© SNOMED International 20	<b>8</b> v1.36.5							
Taxonomy Search	Favo	orites Refset		oncept Details				
Search			G	Concept Details				© 🌣
Options		Type at least 3 characters 🗙 Example: shou fra		ummary Details Diagram Expression Refset	ts Members	References		
Search Mode: Partial ma search mode ✔ Status: Active compon		Search	8	Parents SNOMED CT Concept (SNOMED RT+CTV3)			Stated	Inferred
only - Group by concept			5	Clinical finding 🛧 🗷 No attributes (finding) SCTID: 404684003 404684003   Clinical finding (finding)   Clinical finding (finding) Clinical finding SCTID: 404684003 404684003   Clinical finding (finding)   Clinical finding Clinical finding	5			



Body mass index

otions 👻	ns – Help – <u>loinc.org</u> <u>Go Premium!</u> Set Langua							
From R	bmi Search							
DINC	LongName	Component	Property	Timing	System			
<u>82271-8</u>	Activity metabolic rate/Standard resting metabolic rate [Relative Energy/Time] adjusted for age+sex+race+BMI 1 minute mean Estimated	Activity metabolic rate/Standard resting metabolic rate^^adjusted for age+sex+race+BMI	RelEngRat	1M^mean	^Patient			
<u>728-7</u>	Vital signs, weight, height, head circumference, oximetry, BMI, and BSA panel - HL7.CCDAr1.1	Vital signs, weight, height, head circumference, oximetry, BMI, & BSA panel	-	Pt	^Patient			
<u>353-1</u>	Vital signs, weight, height, head circumference, oxygen saturation and BMI panel	Vital signs, weight, height, head circumference, oxygen saturation & BMI panel	-	Pt	^Patient			
<u>574-4</u>	Body mass index (BMI) [Percentile]	Body mass index	Prctl	Pt	^Patient			
<u>575-1</u>	Body mass index (BMI) [Percentile] Per age	Body mass index	Prctl	Pt	^Patient			
<u>576-9</u>	Body mass index (BMI) [Percentile] Per age and gender	Body mass index	Prctl	Pt	^Patient			

Estimated body mass index greater than 40

Search generated 8 hits in 0.009 secs.

Body mass index (BMI) [Ratio]

Estimated BMI greater than 40

Copyright® 2017 Regenstrief Institute Inc.

Pt

Pt

2

Ratio

Find



^Patient

**^Patient** 

►

Options 🖕

LOINC

<u>82271-8</u>

<u>74728-7</u>

<u>85353-1</u>

59574-4

<u>59575-1</u>

<u>59576-9</u>

<u>39156-5</u>

₹ I

<u>88087-2</u>

#### **RxNav**

NIH) U.S. N	National Library of Medicine							About Dis	sclaimer FAQ	ñ
Navigating	RxNorm Drugs	<ul> <li>String</li> </ul>	r A		llin Ilin [RxCUI = 723	⊗ 31	৫ ৩		Q	
RxNorm Grap	h RxNorm Properties	NDC RxTerms		ill Images	Class View Interaction	-	us			
Views Classic Simple Table Filters	HVRX S Amoxicillin M Ambroxol / Am M Amoxicillin / Br	romhexine	t (24)	Rx S am	Precise Ingredient oxicillin Anhydrous oxicillin sodium oxicillin Trihydrate	(3)	V	S Amoxi Drop S Amoxi-tabs S Amoxil	Name (8) Component (2	4)
H V Rx S	S Amoxicillin 100     S Amoxicillin 100     H Rxsm Amoxicillin 100	) MG/ML 00 MG	•		Navigating RxNorm Drugs		V	S Amoxicillin 100 MG [A S Amoxicillin 100 MG [E M Amoxicillin 1000 MG [A MC [Ausmontin]	Biomox]	5 •
<ul> <li>Group</li> <li>Form</li> <li>Links</li> </ul>	SCD/GPCK H Rx M 12 HR Amoxici V S Amoxicillin 100	) MG Oral Tablet					V	S Amoxi-Drop 50 MG/N S Amoxi-tabs 100 MG 0	Dral Tablet	
● 松 ⊘ Legend @ MIN	Anneniaillin 400	MG/ML Oral Suspection Dose Form Group	p (10)	DFG	Dose Form Group	(5)	SBI	S Amoxi-tabs 150 MG C Amovi table 200 MG C Branded Dose S Amoxi Drop Oral Liqu	Form Group (1	.8)
Pack Multi	Product	avulanate Injectable		нvRx <mark>S</mark> Inje	ctable Product Il Liquid Product	•	V V	S Amoxi Drop Oral Proc S Amoxi Drop Oral Proc S Amoxi-tabs Oral Prod	duct	•



#### **VSAC**

	Value Set Auth	oritv Center					Welcome back,	畠 ericparapini 🔻	
N	U.S. National Libra	ry of Medicine							
Welc	ome Search Value Sets D	ownload					Q Browse Code Syst	tems <b>1</b> Help	
Searc	arch the NLM Value Set Repository. Program: All 🔹 Release: Latest 🔹 Q Search								
Refin	e by: Steward	Code Syste	em 🔹						
	Query: Enter value set i	id, codes, words		]	Clear				
Se	Search Results								
	lts for All : Latest :t a hyperlinked OID to see its valu	e set details.					🖾 Export	Search Results	
	hed Value Sets							۵	
± 0	ownload 🗈 View 🛛 📮 Toggle 🧔 Clear	r	14	Page 1 of	254 🕨 🕨 20 🔻 View	v 1 - 20 of 5,067			
	Name		Code System	Туре	Steward	OID	Co	de Count 🕐	
		×	×	×	×		×	×	
	(Inactive) Encounter Reason		SNOMEDCT	Extensional	PharmacyHIT	2.16.840.1.113762.1.4.1096.153		1	
	(Inactive) Interventions Related to Management, Medication Action P		SNOMEDCT	Extensional	PharmacyHIT	2.16.840.1.113762.1.4.1096.82		1	
	AAN - Encounter CPT Codes		CPT	Extensional	AAN	2.16.840.1.113883.3.2288		20	
	AAN - Encounter Codes Grouping		CPT SNOMEDCT	Grouping	AAN	2.16.840.1.113883.3.2286		27	
	AAN - Encounter SNOMED-CT Code	es	SNOMEDCT	Extensional	AAN	2.16.840.1.113883.3.2287		7	
	AAN - Epilepsy DX Codes - ICD9		ICD9CM	Extensional	AAN	2.16.840.1.113883.3.2272		14	
	AAN ALS ICD10		ICD10CM	Extensional	AAN	2 16 840 1 113762 1 4 1034 65		1	



#### HAI\_VOC.XLS

	А	В	С	D	E	F	
1	Healthcare Associated Infection (H	IAI) Reports, Normative Release 1, vocab	oulary				
2							
3	Each tab in this Workbook contains	an HAI value set or list of single-value bin	dings; the index below provides links to e	ach tab. Three large			
4							
5	The top row of each worksheet ind	icates value set name, OID, and binding. A	list of code system OIDS and names is a	t the bottom of this			
6							
7	Each worksheet contains the codes	s and standard displayNames for the value	set (arranged by code). Additional colum	ns may also give			
8							
9	Special character strings are used	in some instances to permit proper codir	g for the Schematron:				
10	Character string	Represents					
11	®	(Registered)					
12	™	™ (Trademark)					
13	>	>					
14	>=	>=					
15	<	<					
16	<=	<=					
17							
18	Large Value Sets Not Included in t	his Spreadsheet					
	External Link	Value Set Name	Value Set OID	Value Set Binding	codeSystemName	codeSystemOID	
20	http://phinvads.cdc.gov	NHSNBloodProductCodabarCode	2.16.840.1.114222.4.11.3335	STATIC	ABC Codabar	2.16.840.1.113883.6.290	
	http://phinvads.cdc.gov	NHSNBloodProductISBTCode	2.16.840.1.114222.4.11.3334	DYNAMIC	ISBT-128	2.16.840.1.113883.6.18	
22	http://www.wpc-edi.com/taxonon	NHSNClinicalSpecialtyCode	2.16.840.1.114222.4.11.3191	DYNAMIC	NUCCProviderCodes	2.16.840.1.113883.6.101	
23							
24	Index of Tabs / Value Sets Sing	e-Value Bindings (SVBs) are listed at the	end				
25	Tab Name	Value Set Name	Value Set OID	Value Set Binding	Note	1	
26	Administration Location Type	NHSNAdministrationLocationTypeCode	2.16.840.1.114222.4.11.3188	STATIC			
27	<u>AntibioticSuscTest</u>	NHSNAntibioticSuscTest	2.16.840.1.114222.4.11.7161	STATIC			
28	Anitmicrobial Agent AURP	NHSNAntimicrobialAgentAURPCode	2.16.840.1.114222.4.11.3360	DYNAMIC			-
	Introduction Admir	nistrationLocationType   Antimicrobia	IAgentAURP AntibioticSuscTest	ASAClass   BSIE	• + : •	•	



#### **Null Flavor**

#### Expresses details about a lack of value


VALUE	MEANING
NI	No Information (default NULL)
OTH	It is not in the domain for the variable.
NINF	Negative infinite
PINF	Positive infinite
UNK	Unknown
ASKU	It was asked, but it is unknown
NASK	It was not asked
NAV	Temporarily not available. Can be known later.
TRC	Content is greater than zero but cannot be quantified.
MSK	The information exists but cannot be revealed based on business rules (policy, privacy, etc.)
NA	Not applicable



# CDA Templates and HAI Reports



#### **Templates: The Lego Analogy**






#### **HAI Reports**

The HL7 Implementation Guide for Healthcare Associated Infection Reports is a collection of documents for NHSN reporting

- Population Summary Reports
  - ARO Reporting
  - AUP Summary Report
  - ICU Summary Report
  - ..
- Single Person Reports
  - HAI AUR Antimicrobial Resistance Option
  - HAI Bloodstream Infection Report
  - ...





## **Evolution of the HAI IG**

- HAI Reporting has moved through several releases most notably:
- Early Releases (2008 2013)
  - R1 -> R9
  - Incremental changes, draft standard
- First Normative Release (2013)
  - AU/AUR Reporting is Introduced
- Second Normative Release (2015)



# **Troubleshooting Scenario**

Using the HAI IG



#### **Materials**

Ø	infrastructure	
Ø	processable	The NHSN HAI Implementation
Ø	xml_sample_files	Guide
Ø	CDAR2L3_IG_HAIRPT_DSTU_R9_2013JAN.docx Authors: Chris Cole	
Ø	generate-narrative.xsl Type: XSLT Stylesheet	
Ø	Type: Schematron Schema	
Ø	hai_errors.xsl Type: XSLT Stylesheet	Source of truth for HAI value sets
Ø	hai_manual_checks.xsl Type: XSLT Stylesheet	3003
Ø	hai_voc.xlsx Authors: Jingdong Li	


California Department of **PublicHealth** 

#### **Troubleshooting Scenario**

- The CDA zip file that was obtained from the vendor system contained some CDA files that were rejected by NHSN on import.
- Received an error output PDF file.



#### **Output Walkthrough**





## **Output Walkthrough**

#### • CONF: 4786

- 5. SHALL contain exactly one [1..1] statusCode (CONF:11338).
  - a. This statusCode SHALL contain exactly one [1..1] @code="completed" Completed (CodeSystem: ActStatus 2.16.840.1.113883.5.14 STATIC) (CONF:2062).
  - 5. SHALL contain exactly one [1..1] value (CONF:2063).
    - a. In an infection-type report, a criterion is reported as a code. The value of @xsi:type SHALL be CD and the value of @code SHALL be selected from Value Set 2.16.840.1.114222.4.11.3195 NHSNCriterionOfDiagnosisCode DYNAMIC (CONF:4786).
    - b. In an Evidence of Infection (Dialysis) Report, (CONF:10908).
      - To record a criterion of diagnosis as a code, the value of @xsi:type SHALL be CD and the value of @code SHALL be selected from Value Set 2.16.840.1.114222.4.11.3195 NHSNCriterionOfDiagnosisCode DYNAMIC (CONF:10909).
      - ii. To record a criterion not included in the NHSNCriterionOfDiagnosisCode value set, the value of @xsi:type SHALL be ST and a text value SHALL be present (CONF:10910).



#### **Output Walkthrough**

- a. In an infection-type report, a criterion is reported as a code. The value of @xsi:type SHALL be CD and the value of @code SHALL be selected from Value Set 2.16.840.1.114222.4.11.3195 NHSNCriterionOfDiagnosisCode DYNAMIC (CONF:4786).
  - The value in the report must be selected from the NHSNCriterionOfDiagnosisCode value set



#### Locate in HAI\_VOC.xlsx

	А	В	С	D
22	http://www.wpc-edi.com/taxonor	NHSNClinicalSpecialtyCode	2.16.840.1.114222.4.11.3191	DYNAMIC
23				
24	Index of Tabs / Value Sets Sing	e-Value Bindings (SVBs) are listed at the o	end	
25	Tab Name	Value Set Name	Value Set OID	Value Set Binding
26	Administration Location Type	NHSNAdministrationLocationTypeCode	2.16.840.1.114222.4.11.3188	STATIC
27	<u>AntibioticSuscTest</u>	NHSNAntibioticSuscTest	2.16.840.1.114222.4.11.7161	STATIC
28	Anitmicrobial Agent AURP	NHSNAntimicrobialAgentAURPCode	2.16.840.1.114222.4.11.3360	DYNAMIC
29	ASA Class	NHSNASAClassCode	2.16.840.1.113883.13.10	STATIC
30	BSI Evidence Type	NHSNBloodstreamInfectionEvidenceType	2.16.840.1.113883.13.7	DYNAMIC
31	Catheter Type	NHSNCatheterTypeCoce	2.16.840.1.114222.4.11.3185	STATIC
32	<u>Certainty</u>	NHSNCertaintyCode	2.16.840.1.114222.4.11.3387	STATIC
33	<u>Closure Technique</u>	NHSNClosureTechniqueCode	2.16.840.1.114222.4.11.6051	STATIC
34	Criterion of Diagnosis	NHSNCriteriaOfDiagnosisCode	2.16.840.1.114222.4.11.3195	DYNAMIC
35	Drug Susceptibility Finding	NHSNDrugSusceptibilityFindingCode	2.16.840.1.113883.13.13	STATIC
36	Drug Susceptibility Tests	NHSNDrugSusceptibilityTestsCode	2.16.840.1.113883.13.15	DYNAMIC
37	<u>Eligibility</u>	NHSNEligibilityCode	2.16.840.1.114222.4.11.3248	DYNAMIC
38	Encounter Type	NHSNEncounterTypeCode	2.16.840.1.113883.13.1	STATIC
39	<u>EthnicityGroup</u>	CDC Ethnicity Group	2.16.840.1.114222.4.11.837	STATIC
40	Healthcare Service Location	NHSNHealthcareServiceLocationCode	2.16.840.1.113883.13.19	DYNAMIC
41	Hip Replacement	NHSNHipReplacementCode	2.16.840.1.113883.13.3	STATIC
42	<u>Imputability</u>	NHSNImputabilityCode	2.16.840.1.114222.4.11.3388	STATIC
43	Infection Condition	NHSNInfectionConditioncode	2.16.840.1.114222.4.11.3196	DYNAMIC
44	Infection Risk Factors	NHSNInfectionRiskFactorsCode	2.16.840.1.113883.13.6	STATIC
45	Infection Type	NHSNInfectionTypeCode	2.16.840.1.113883.13.20	DYNAMIC
46	Insertion Site	NHSNInsertionSiteCode	2.16.840.1.114222.4.11.3180	DYNAMIC
47	Knee Replacement	NHSNKneeReplacementCode	2.16.840.1.113883.13.4	STATIC
48	Occasion of Detection	NHSNOccassionOfDetectionCode	2.16.840.1.113883.13.12	DYNAMIC
49	Organism AST	NHSNOrganismASTCode	2.16.840.1.114222.4.11.3283	DYNAMIC
50	Olg3ome Type	NSHNOutcomeTypeCode	2.16.840.1.114222.4.11.3386	STATIC
-	Introduction Admin	nistrationLocationType   Antimicrobial	AgentAURP   AntibioticSuscTest	ASAClass   BSIEvide



# Validation



#### Validation

Implementation Guide

Is it CDA? Tested by Schema

Is it HAI? Tested by Schematron



Is it a Car? (4 wheels, seats, headlights, steering)

Is it a Ford Mustang? (powerful engine, muscular body, big wheels)



## Validation: Sample Implementation

#### • Online CDA Validator

- Implements a basic multi-stage validation pipeline
- Freely available
- Validation for most SDWG-developed IGs
- http://www.lantanag roup.com/validator

CDA Validator					
Lantana CONSULTING GROUP					
Upload the XML or zip file you wish to validate (Note: The size of the uploaded zip file must be less than 5Mb):					
Choose File No file chosen					
Select your desired validation path:					
Base Standard Only					
<ul> <li>ODA_R2</li> <li>SPL Release 2</li> </ul>					
Base Standard Plus Templated Validation					
HL7 Balloted Implementation Guides					
<ul> <li>CCD validation</li> <li>CRS validation</li> <li>History and Physical (DSTU R1)</li> <li>Consult Note (DSTU R1)</li> <li>Operative Note (DSTU R1)</li> </ul>					
<ul> <li>Healthcare Associated Infection (HAI) Reporting (DSTU R2D2.1; Dec 2014)</li> <li>Healthcare Associated Infection (HAI) Reporting (Normative R2N; June 2015)</li> </ul>					
Consolidated CDA (C-CDA) (HL7 Balloted IGs)					
<ul> <li>CDA Consolidation Release 1 (December, 2011)</li> <li>CDA Consolidation Release 1.1 (*** Obsolete *** - Last Updated December 14, 2012. Only for Connectathon Validation)</li> <li>CDA Consolidation Release 1.1 plus all SDWG errata through 2014-04-08</li> <li>Consolidated CDA (C-CDA DSTU Release 2) (Nov 2014)</li> </ul>					



#### Validation vs. Verification

#### Validation:

Ensure the report format and structure is correct.

#### Verification:

Ensure the information found within the report is accurate.



# Rendering



#### NHSN Transformation and Stylesheet

- Developed by NHSN
- Creates CDA Narrative from machine readable entries
  - Recreates the forms they are representing



#### Example



Patient	Ned Nuclear	led Nuclear					
Admission Date	January 15, 2009	nuary 15, 2009					
Date of birth	November 25, 1954	November 25, 1954 Sex Male					
Race	Information not available	Ethnicity	Not Hispanic or Latino				
Contact info	address not availablePatient IDs123456Telecom information not available(2.16.840.1.113883.3.117.1.1.5.1)						
Document Id	20202201 (2.16.840.1.113883.3.117.1.1.5.2.1.1.2)	20202201 (2.16.840.1.113883.3.117.1.1.5.2.1.1.2)					
Document Created	August 7, 2008						
Author	anAuthorID (2.16.840.1.113883.3.117.1.1.5.1.1.2)						
Encounter Date	From January 15, 2009						
Encounter Location	2.16.840.1.113883.3.117.1.1.5.1.1						
Document maintained by	Document maintained by 2.16.840.1.114222.4.3.2.11						
Legal authenticator	Legal authenticator aLegalAuthenticatorID (2.16.840.1.113883.3.117.1.1.5.1.1.2) signed date/time: August 7, 2008						

#### <u>Findings</u>

	Specimen type Date Specimen Collected		In-facility location of patient when specimen was drawn				
Blood specimen January 21, 2009 9W Medical/Surgical c				al care unit			
	Microbiology Studies: Pathogen Isolate						
	Staphylococcus aureus						
	Staph Aureus Specific	: Test		Result			
	Oxacillin Resistant Sta	phylococcus sp isolate [Presence] in Isolate	e by Latex agglutination	Negative			
Bacterial methicillin resistance (mecA) gene [Presence] by Probe and target amplification         Positive           method         Positive         Positive							

cHealth

## Agenda

- Introduction
- Overview of the Antimicrobial Resistance Module
- AR Data Requirements
- NHSN Metrics and Benchmarks
- CDA and the NHSN HAI IG
- Our Support
- Resources



## **Our Support**

- Implementation Support
- Verification of reporting outputs
- Customized resources and trainings
- Learning collaborative



## Agenda

- Introduction
- Overview of the Antimicrobial Resistance Module
- AR Data Requirements
- NHSN Metrics and Benchmarks
- CDA and the NHSN HAI IG
- Our Support

#### Resources



## **AR Toolkit**

- The AR toolkit provides implementers with the specific identifiers, locations, vocabulary, constraints, etc. required in the CDA.
- AR Option Overview for Vendors.docx
  - A Review of AR Option.
- Information Data Module(IDM) for Vendors
  - Includes business rules, coding information and codes used during development of the CDA.
- 57.123\_AUR Micro Electronic Upload Tables
  - View of the AR Option form to offer a visual of data elements required for submission.
- ARO organism mapping.xlsx
  - Lists the valid AR Option pathogens.
  - Refer to AntiP tab in the IDM for details.
- AR\_CDA\_Vendor Samples

   Contains Antimicrobial Resistance (AR) xml samples of various AR-numerator CDAs.



#### **Important Links**

- <u>National Healthcare Safety Network (NHSN)</u>: http://www.cdc.gov/nhsn/
- <u>Surveillance for Antimicrobial Use (AU) and Antimicrobial Resistance (AR) Options</u>: http://www.cdc.gov/nhsn/acute-care-hospital/aur/index.html
- <u>Direct link to AUR Module protocol</u>: https://www.cdc.gov/nhsn/pdfs/pscmanual/11pscaurcurrent.pdf
- <u>NHSN CDA Submission Support Portal (CSSP)</u> https://www.cdc.gov/nhsn/cdaportal/index.html
- <u>HL7 Implementation Guide</u> for CDA<sup>®</sup> Release 2: Healthcare Associated Infection (HAI) Reports, Release 1 – US Realm, August 2013 http://www.hl7.org/implement/standards/product\_brief.cfm?product\_id=20



#### Questions

